NRG GY018

Primary Category:

Treatment Protocols

Disease Category:

Endometrial, Gynecologic

Status:

Closed

A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475, NSC #776864) in Addition to Paclitaxel and Carboplatin for Measurable Stage III or IVB or Recurrent Endometrial Cancer

Eligible for screening study DCP 001

GY018 is closed to accrual, effective December 6, 2022.

NCT#03914612